Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Last trade$9.63
Day change-$0.31 (-3.12%)
Day range$9.19 – $10.75
Volume297,395
Market cap$584M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$583.86M
Price / earnings
—
Price / book
2.56×
Price / sales
—
EV / sales
—
EV / EBITDA
-8.19×
Profitability
Earnings per share
-$1.02
Return on assets
-25.27%
Return on equity
-26.21%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
26.58×
Quick ratio
26.58×
Cash ratio
5.03×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$53.64M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CLYM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$5.85M
$5.65M
$5.84M
$5.56M
$5.82M
$4.1M
$5.69M
$4.95M
Research and development
$11.04M
$9.71M
$9.37M
$13.74M
$9.07M
$6.58M
$17.33M
$5.96M
Total operating expenses
$16.89M
$15.36M
$15.21M
$19.3M
$14.89M
$10.68M
$23.02M
$10.91M
Operating income
-$16.89M
-$15.36M
-$15.21M
-$19.3M
-$14.89M
-$10.68M
-$23.02M
-$10.91M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$15.03M
-$13.5M
-$13.72M
-$17.52M
-$12.74M
-$8.67M
-$20.78M
-$8.42M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$15.03M
-$13.5M
-$13.72M
-$17.52M
-$12.74M
-$8.67M
-$20.78M
-$8.42M
Net income attributable to common shareholders
-$15.03M
-$13.5M
-$13.72M
-$17.52M
-$12.74M
-$8.67M
-$20.78M
-$8.42M
EBITDA
-$16.7M
-$15.33M
-$15.17M
-$19.27M
-$14.86M
-$10.64M
-$23.02M
-$10.91M
Basic earnings per share
-$0.18
-$0.18
-$0.20
-$0.26
-$0.19
-$0.13
-$0.31
-$0.12
Diluted earnings per share
-$0.18
-$0.18
-$0.20
-$0.26
-$0.19
-$0.13
-$0.31
-$0.12
Recent news
Company coverage with links to the original publishers.
Climb Bio announced Phase 2 data for budoprutug, an anti-CD19 monoclonal antibody, showing promising results in primary membranous nephropathy (pMN) treatment. The 200 mg dose demonstrated B-cell depletion, 70% PLA2R antibody reduction, and immunologic remission at 12 weeks. Higher 600 mg doses showed greater drug exposure and deeper B-cell depletion. The drug was generally well-tolerated with no serious adverse events. A separate case study showed sustained three-year steroid-free remission in a minimal change disease patient.
The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.
Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company, announced that its executive team will participate in three upcoming healthcare and biotech conferences in February and March 2026, including Guggenheim's Emerging Outlook: Biotech Summit, Oppenheimer's 36th Annual Healthcare Life Sciences Conference, and Leerink Global Healthcare Conference. Live webcasts will be available on the company's investor relations website.
Climb Bio granted a non-statutory stock option to a new employee for 120,000 shares at $1.76 per share, vesting over four years with standard stock option terms.
Climb Bio presented preclinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, and long-term clinical data for budoprutug, an anti-CD19 monoclonal antibody showing potential in primary membranous nephropathy treatment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.